147 related articles for article (PubMed ID: 35125763)
1. Pazopanib-Induced Asymptomatic Necrotizing Pancreatitis Diagnosed on
Pereira M; Shivdasani D; Singh N
Indian J Nucl Med; 2021; 36(4):432-434. PubMed ID: 35125763
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report.
Baraibar I; Quílez A; Salas D; Román M; Rolfo C; Pérez-Gracia JL; Gil-Bazo I
Mol Clin Oncol; 2017 May; 6(5):651-654. PubMed ID: 28529741
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic
Sachpekidis C; Karampinis I; Jakob J; Kasper B; Nowak K; Pilz L; Attenberger U; Gaiser T; Derigs HG; Schwarzbach M; Hohenberger P; Dimitrakopoulou-Strauss A; Ronellenfitsch U
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181713
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib-Induced Severe Acute Pancreatitis.
Kawakubo K; Hata H; Kawakami H; Kuwatani M; Kawahata S; Kubo K; Imafuku K; Kitamura S; Sakamoto N
Case Rep Oncol; 2015; 8(2):356-8. PubMed ID: 26464570
[TBL] [Abstract][Full Text] [Related]
5. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Van Tine BA; Trent JC
Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
[TBL] [Abstract][Full Text] [Related]
6. Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.
Vlenterie M; Oyen WJ; Steeghs N; Desar IME; Verheijen RB; Koenen AM; Grootjans W; DE Geus-Oei LF; VAN Erp NP; VAN DER Graaf WT
Anticancer Res; 2019 Mar; 39(3):1309-1316. PubMed ID: 30842163
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized
Ravoori MK; Singh SP; Lee J; Bankson JA; Kundra V
Radiology; 2017 Dec; 285(3):830-838. PubMed ID: 28707963
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Chronic active hepatitis induced by Pazopanib mimicking hypervascular liver metastases in a patient with recurrent soft tissue sarcoma: A case report.
Ezponda A; De La Huebra IG; Calvo M; Idoate MÁ; Vivas I
Oncol Lett; 2018 Sep; 16(3):4043-4048. PubMed ID: 30128026
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04).
Ronellenfitsch U; Karampinis I; Dimitrakopoulou-Strauss A; Sachpekidis C; Jakob J; Kasper B; Nowak K; Pilz L; Attenberger U; Gaiser T; Derigs HG; Schwarzbach M; Hohenberger P
Ann Surg Oncol; 2019 May; 26(5):1332-1339. PubMed ID: 30843160
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib in advanced soft tissue sarcomas.
Lee ATJ; Jones RL; Huang PH
Signal Transduct Target Ther; 2019; 4():16. PubMed ID: 31123606
[TBL] [Abstract][Full Text] [Related]
13. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
Karch A; Koch A; Grünwald V
Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
[TBL] [Abstract][Full Text] [Related]
16. Rechallenge with Multi-Targeted Tyrosine Kinase Inhibitors in Patients with Advanced Soft Tissue Sarcoma: A Single-Center Experience.
Liu J; Deng YT; Wu X; Jiang Y
Cancer Manag Res; 2021; 13():2595-2601. PubMed ID: 33776477
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
Subbiah V; Meyer C; Zinner R; Meric-Bernstam F; Zahurak ML; O'Connor A; Roszik J; Shaw K; Ludwig JA; Kurzrock R; Azad NA
Clin Cancer Res; 2017 Aug; 23(15):4027-4034. PubMed ID: 28377484
[No Abstract] [Full Text] [Related]
18. Pazopanib for the treatment of soft-tissue sarcoma.
Heudel P; Cassier P; Derbel O; Dufresne A; Meeus P; Thiesse P; Ranchère-Vince D; Blay JY; Ray-Coquard I
Clin Pharmacol; 2012; 4():65-70. PubMed ID: 23204874
[TBL] [Abstract][Full Text] [Related]
19. Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring
Campoverde L; Camacho F; Alessandrino F; Evans MG; Elliot A; Rosenberg A; Trent J
Front Oncol; 2023; 13():1215003. PubMed ID: 37829338
[TBL] [Abstract][Full Text] [Related]
20. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
